Apilimod

DB05611InvestigationalSmall molecule

Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.

Mechanism: Pharmacologically active on 1-phosphatidylinositol 3-phosphate 5-kinase
Curator reviewed
Primary indication: Investigated for use/treatment in crohn's disease and psoriasis and psoriatic disorders.Curator reviewed
Formula / weight: C₂₃H₂₆N₆O₂ · 418.501 g/mol (avg)
Code names: STA-5326

Resolves to

Compound

Structure

InChIKeyHSKAZIJJKRAJAV-KOEQRZSOSA-NSMILESCC1=CC=CC(\C=N\NC2=CC(=NC(OCCC3=CC=CC=N3)=N2)N2CCOCC2)=C1

Targets

What you can answer from here — as of August 30, 2026

2Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

9Clinical trialsPhase, status and sponsor resolved per trial

6+ReferencesStructured and connected to the statements they support

Which drugs share a target with Apilimod, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.